文献速递创伤与烧伤重症综合管理与镇静镇痛心脑血管急症

重型创伤性脑损伤患者静脉血栓栓塞预防时机与药物选择对静脉血栓栓塞事件、死亡率、神经外科干预及出院去向的影响

Association of timing and agent for venous thromboembolism prophylaxis in patients with severe traumatic brain injury on venous thromboembolism events, mortality, neurosurgical intervention, and discharge disposition.
PubMed 文献 · J Trauma Acute Care Surg · 2024-05-15
一句话结论重型TBI中,LMWH较低分子肝素以外药物降低VTE发生率且不增加死亡或神经外科干预,≤48小时启动降低VTE但增加非致命开颅手术,作者认为LMWH为首选且≤48小时启动应权衡利弊。

这项比较效果研究纳入2017年1月1日至2022年6月1日35家一级和二级创伤中心的重型TBI患者(简明损伤定级头部评分3、4或5分),比较无VTE预防、LMWH≤48小时、LMWH>48小时、肝素≤48小时和肝素>48小时各组,采用倾向评分匹配及logistic回归评估院内死亡、VTE和出院去向,以VTE预防启动后神经外科干预评估颅内出血扩大。12,879例中32%无预防、36%用LMWH、32%用肝素;总死亡率8.3%,LMWH≤48小时组最低(4.1%)。LMWH组VTE率1.6% vs 4.5%(OR 2.98,95%CI 1.40-6.34,p=0.005),早期预防组VTE率2.0% vs 3.5%(OR 1.76,95%CI 1.15-2.71,p=0.01),均未增加死亡或神经外科干预。早期预防与更多非致命颅内手术相关(p<0.001),但启动预防后接受神经外科干预者死亡率、放弃治疗率及不良出院去向无差异(p=0.7、p=0.1、p=0.5)。作者认为LMWH是重型TBI首选VTE预防药物,≤48小时启动应结合上述风险与获益考虑。

要点

  • 重型TBI(AIS头部3、4或5分)中,LMWH组VTE发生率1.6% vs 4.5%(OR 2.98,95%CI 1.40-6.34,p=0.005),未增加死亡或神经外科干预。
  • ≤48小时启动VTE预防组VTE发生率2.0% vs 3.5%(OR 1.76,95%CI 1.15-2.71,p=0.01),死亡率无差异(p=1.0)。
  • 早期VTE预防与更多非致命颅内手术相关(p<0.001),但启动预防后接受神经外科干预者死亡率、放弃治疗率、不良出院去向无差异(p=0.7、p=0.1、p=0.5)。
  • 12,879例中32%无VTE预防、36%用LMWH、32%用肝素;总死亡率8.3%,LMWH≤48小时组最低(4.1%)。
  • 作者认为LMWH是重型TBI首选VTE预防药物,≤48小时启动应结合上述风险与获益考虑。

适用人群与场景

  • 重型创伤性脑损伤患者,简明损伤定级(AIS)头部评分3、4或5分。
  • 数据来自35家一级和二级创伤中心,收集时间为2017年1月1日至2022年6月1日。

诊断标准与关键阈值

  • 重型TBI定义为简明损伤定级(AIS)头部评分3、4或5分。
  • 分析分组:无VTE预防、LMWH≤48小时、LMWH>48小时、肝素≤48小时、肝素>48小时。

研究设计与关键结果

  • 比较效果研究,纳入12,879例重型TBI患者,数据来自35家一级和二级创伤中心(2017年1月1日至2022年6月1日)。
  • 分组:32%无VTE预防、36%用LMWH、32%用肝素。
  • 总死亡率8.3%,LMWH≤48小时组最低(4.1%)。
  • LMWH组VTE发生率1.6% vs 4.5%,OR 2.98(95%CI 1.40-6.34),p=0.005,未增加死亡或神经外科干预。
  • 早期预防组VTE发生率2.0% vs 3.5%,OR 1.76(95%CI 1.15-2.71),p=0.01,死亡率无差异(p=1.0)。
  • 早期VTE预防与更多非致命颅内手术相关(p<0.001);启动预防后接受神经外科干预者死亡率、放弃治疗率、不良出院去向无差异(p=0.7、p=0.1、p=0.5)。

证据类型、等级与局限

  • 证据类型:比较效果研究;证据等级:治疗/护理管理,Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,LMWH是重型TBI首选的VTE预防药物,与较低VTE发生率相关且不增加死亡或神经外科干预。
  • 作者认为,≤48小时启动VTE预防可降低VTE发生率并增加非致命神经外科干预,但不影响死亡率,应结合这些风险与获益考虑启动时机。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Trauma patients are at increased risk for venous thromboembolism events (VTEs). The decision of when to initiate VTE chemoprophylaxis (VTEP) and with what agent remains controversial in patients with severe traumatic brain injury (TBI).

METHODS: This comparative effectiveness study evaluated the impact of timing and agent for VTEP on outcomes for patients with severe TBI (Abbreviated Injury Scale head score of 3, 4, or 5). Data were collected at 35 Level 1 and 2 trauma centers from January 1, 2017, to June 1, 2022. Patients were placed into analysis cohorts: no VTEP, low-molecular-weight heparin (LMWH) ≤48 hours, LMWH >48 hours, heparin ≤48 hours, and heparin >48 hours. Propensity score matching accounting for patient factors and injury characteristics was used with logistic regression modeling to evaluate in-hospital mortality, VTEs, and discharge disposition. Neurosurgical intervention after initiation of VTEP was used to evaluate extension of intracranial hemorrhage.

RESULTS: Of 12,879 patients, 32% had no VTEP, 36% had LMWH, and 32% had heparin. Overall mortality was 8.3% and lowest among patients receiving LMWH ≤48 hours (4.1%). Venous thromboembolism event rates were lower with use of LMWH (1.6% vs. 4.5%; odds ratio, 2.98; 95% confidence interval, 1.40-6.34; p = 0.005) without increasing mortality or neurosurgical interventions. Venous thromboembolism event rates were lower with early prophylaxis (2.0% vs. 3.5%; odds ratio, 1.76; 95% confidence interval, 1.15-2.71; p = 0.01) without increasing mortality ( p = 1.0). Early VTEP was associated with more nonfatal intracranial operations ( p < 0.001). However, patients undergoing neurosurgical intervention after VTEP initiation had no difference in rates of mortality, withdrawal of care, or unfavorable discharge disposition ( p = 0.7, p = 0.1, p = 0.5).

CONCLUSION: In patients with severe TBI, LMWH usage was associated with lower VTE incidence without increasing mortality or neurosurgical interventions. Initiation of VTEP ≤48 hours decreased VTE incidence and increased nonfatal neurosurgical interventions without affecting mortality. Low-molecular-weight heparin is the preferred VTEP agent for severe TBI, and initiation ≤48 hours should be considered in relation to these risks and benefits.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Johnson PL, Dualeh SHA, Ward AL, et al. Association of timing and agent for venous thromboembolism prophylaxis in patients with severe traumatic brain injury on venous thromboembolism events, mortality, neurosurgical intervention, and discharge disposition. J Trauma Acute Care Surg. 2024. PMID: 38745357. doi:10.1097/TA.0000000000004383

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。